In the recent announcement, Neuren highlighted that the U.S. Patent and Trademark Office has issued a Notice of Allowance for two new patents. One for NNZ-2566 and the second for NNZ-2591;
Seven patents for composition, methods of use and formulation have previously been issued for NNZ-2566 and three patents for composition and methods of use have been issued for NNZ-2591.
Which means we are still waiting for six more for NNZ-2566 and two more for NNZ-2591.
This will further enhance the commercial value of Neuren's drug pipeline as highlighted in announcement by CEO, Larry Glass.
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.69 |
Change
0.210(1.27%) |
Mkt cap ! $2.078B | |||
| Open | High | Low | Value | Volume |
| $16.48 | $16.74 | $16.28 | $1.554M | 94.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 56 | $16.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.71 | 47 | 2 |
View Market Depth
| Last trade - 12.33pm 28/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |